North America Needle Free Injections Market Outlook to 2023

North America Needle Free Injections Market Outlook to 2023


  • Products Id :- GDMECR0669DB
  • |
  • Pages: 95
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

North America Needle Free Injections Market Outlook to 2023

Summary

GlobalData's new report, "North America Needle Free Injections Market Outlook to 2023", provides key market data on the North America Needle Free Injections market. The report provides value, in millions of US dollars, volume (in units) and and average prices (USD) for Needle Free Injections.

The report also provides company shares and distribution shares data for each of these market segments, and global corporate-level profiles of the key market participants. Based on the availability of data for the particular market and country, information related to pipeline products, news and deals is available in the report.

Extensive interviews are conducted with key opinion leaders (KOLs), physicians and industry experts to validate the market size, company share and distribution share data and analysis.

Scope

Market size and company share data for Needle Free Injections.

Annualized market revenues (USD million) and volume (units) data for each of the market segments. Data is provided from 2009 to 2016 and forecast to 2023.

2016 company shares and distribution shares data for each of the market segments.

Global corporate-level profiles of key companies operating within the North America Needle Free Injections market.

Key players covered include INJEX-Equidyne Systems, Bioject Medical Technologies Inc and Antares Pharma Inc.

Reasons to buy

Develop business strategies by identifying the key market segments poised for strong growth in the future.

Develop market-entry and market expansion strategies.

Design competition strategies by identifying who-stands-where in the market.

Develop investment strategies by identifying the key market segments expected to register strong growth in the near future.

What are the key distribution channels and what's the most preferred mode of product distribution-Identify, understand and capitalize.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

1 Table of Contents

1 Table of Contents 2

1.1 List of Tables 5

1.2 List of Figures 6

2 Introduction 7

2.1 What Is This Report About? 7

2.2 Needle Free Injections Market Segmentation 7

2.3 Definitions of Markets Covered in the Report 7

3 Needle Free Injections Market, North America 8

3.1 Needle Free Injections Market, North America, Revenue ($m), 2009-2023 8

3.2 Needle Free Injections Market, North America, Revenue ($m), 2009-2016 10

3.3 Needle Free Injections Market, North America, Revenue ($m), 2016-2023 11

3.4 Needle Free Injections Market, North America, Volume (Units), 2009-2023 12

3.5 Needle Free Injections Market, North America, Volume (Units), 2009-2016 13

3.6 Needle Free Injections Market, North America, Volume (Units), 2016-2023 14

3.7 Needle Free Injections Market, North America, Company Share by Revenue ($m), 2016 15

4 Needle Free Injections Market, Canada 17

4.1 Needle Free Injections Market, Canada, Revenue ($m), 2009-2016 17

4.2 Needle Free Injections Market, Canada, Revenue ($m), 2016-2023 18

4.3 Needle Free Injections Market, Canada, Volume (Units), 2009-2016 19

4.4 Needle Free Injections Market, Canada, Volume (Units), 2016-2023 20

4.5 Needle Free Injections Market, Canada, Average Price ($), 2009-2023 21

4.6 Needle Free Injections Market, Canada, Distribution Share by Revenue ($m), 2015-2016 22

4.7 Needle Free Injections Market, Canada, Company Share by Revenue ($m), 2016 23

5 Needle Free Injections Market, Mexico 25

5.1 Needle Free Injections Market, Mexico, Revenue ($m), 2009-2016 25

5.2 Needle Free Injections Market, Mexico, Revenue ($m), 2016-2023 26

5.3 Needle Free Injections Market, Mexico, Volume (Units), 2009-2016 27

5.4 Needle Free Injections Market, Mexico, Volume (Units), 2016-2023 28

5.5 Needle Free Injections Market, Mexico, Average Price ($), 2009-2023 29

5.6 Needle Free Injections Market, Mexico, Distribution Share by Revenue ($m), 2015-2016 30

5.7 Needle Free Injections Market, Mexico, Company Share by Revenue ($m), 2016 31

6 Needle Free Injections Market, United States 33

6.1 Needle Free Injections Market, United States, Revenue ($m), 2009-2016 33

6.2 Needle Free Injections Market, United States, Revenue ($m), 2016-2023 34

6.3 Needle Free Injections Market, United States, Volume (Units), 2009-2016 35

6.4 Needle Free Injections Market, United States, Volume (Units), 2016-2023 36

6.5 Needle Free Injections Market, United States, Average Price ($), 2009-2023 37

6.6 Needle Free Injections Market, United States, Distribution Share by Revenue ($m), 2015-2016 38

6.7 Needle Free Injections Market, United States, Company Share by Revenue ($m), 2016 39

7 Overview of Key Companies in North America Needle Free Injections Market 41

7.1 INJEX-Equidyne Systems 41

7.1.1 Company Overview 41

7.2 Bioject Medical Technologies Inc 41

7.2.1 Company Overview 41

7.3 Antares Pharma Inc 41

7.3.1 Company Overview 41

7.4 PharmaJet Inc 41

7.4.1 Company Overview 41

7.5 MK Global Co. 42

7.5.1 Company Overview 42

8 Needle Free Injections Market Pipeline Products 43

9 Recent Developments 44

9.1 Corporate Communications 44

9.1.1 Jul 17, 2017: Baxter Appoints Cathy R. Smith to its Board 44

9.1.2 Jun 06, 2017: Valeritas Appoints Peter J. Devlin to Chairman of its Board of Directors 44

9.1.3 Apr 10, 2017: Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors 44

9.1.4 Apr 06, 2017: Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency 45

9.1.5 Feb 08, 2017: Baxter Appoints Dr. Stephen Oesterle to Its Board 45

9.1.6 Jan 05, 2017: Zogenix Announces CFO Transition 45

9.1.7 Nov 30, 2016: Valeritas Elects Joe Mandato, Ph.D., Experienced Medical Device Executive and Investor, to Board of Directors 46

9.1.8 Nov 17, 2016: OSE Immunotherapeutics announces the online publication of positive Phase 1 clinical results with FR104 in the Journal of Immunology 47

9.1.9 Nov 15, 2016: Oncoceutics Presents Abstracts on ONC201 at 2016 American Society of Hematology Meeting 48

9.1.10 Nov 14, 2016: Olympus VISERA 4K UHD Receives "Excellence in Surgical Products Awards," Minimally Invasive Surgical Product Category 49

9.1.11 Oct 31, 2016: Antares Pharma Appoints Fred M. Powell, Senior Vice President and Chief Financial Officer 50

9.1.12 Oct 10, 2016: Professor Ian Meredith To Join Boston Scientific As Executive Vice President And Global Chief Medical Officer 50

9.1.13 Sep 22, 2016: Industry Veteran Katherine D. Crothall, PhD to Join Valeritas Board of Directors 51

9.1.14 Aug 16, 2016: Valeritas Appoints Erick J. Lucera as Chief Financial Officer 51

9.2 Financial Announcements 52

9.2.1 May 15, 2017: Aradigm Announces First Quarter 2017 Financial Results 52

9.2.2 May 12, 2017: Valeritas Reports First Quarter 2017 Financial Results 52

9.2.3 May 10, 2017: ICU Medical Announces First Quarter 2017 Results 53

9.2.4 May 09, 2017: Antares Pharma Reports First Quarter 2017 Operating and Financial Results 54

9.2.5 May 04, 2017: Zogenix Reports First Quarter 2017 Financial Results 55

9.2.6 May 02, 2017: Merck Announces First-Quarter 2017 Financial Results 55

9.2.7 Apr 27, 2017: Boston Scientific Announces Results For First Quarter 2017 57

9.2.8 Apr 26, 2017: Baxter Reports First-Quarter 2017 Results and Increases Financial Outlook for Full-Year 2017 58

9.2.9 Mar 28, 2017: Aradigm Announces Fourth Quarter 2016 and Full Year Financial Results 59

9.2.10 Mar 14, 2017: Antares Pharma Reports Fourth Quarter and Full Year 2016 Operating and Financial Results 60

9.2.11 Mar 09, 2017: Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results 61

9.2.12 Mar 01, 2017: ICU Medical Announces Fourth Quarter and Fiscal Year 2016 Results 63

9.2.13 Feb 21, 2017: Valeritas Reports Fourth Quarter and Full Year 2016 Financial Results 63

9.2.14 Feb 02, 2017: Boston Scientific Announces Results For Fourth Quarter And Full Year Ended December 31, 2016 64

9.2.15 Feb 02, 2017: Merck Announces Fourth-Quarter and Full-Year 2016 Financial Results 65

9.2.16 Feb 01, 2017: Baxter Reports 2016 Fourth-Quarter and Full-Year Results 67

9.2.17 Nov 10, 2016: Valeritas Reports Third Quarter 2016 Financial Results 69

9.2.18 Nov 09, 2016: Antares Pharma Reports Third Quarter 2016 Financial and Operating Results 69

9.2.19 Nov 09, 2016: Aradigm Announces Third Quarter 2016 Financial Results 71

9.2.20 Nov 09, 2016: ICU Medical Announces Third Quarter 2016 Results 72

9.2.21 Nov 08, 2016: Zogenix Provides Corporate Update and Reports Third Quarter 2016 Financial Results 72

9.2.22 Oct 26, 2016: Boston Scientific Announces Results For Third Quarter 2016 73

9.2.23 Oct 25, 2016: Baxter Reports Third Quarter 2016 Results and Increases Financial Outlook For Full-Year 2016 75

9.2.24 Oct 25, 2016: Merck Announces Third-Quarter 2016 Financial Results 76

9.2.25 Aug 10, 2016: Aradigm Announces Second Quarter 2016 Financial Results 78

9.2.26 Aug 10, 2016: Valeritas Reports Second Quarter 2016 Financial Results 79

9.2.27 Aug 09, 2016: Antares Pharma Reports Second Quarter 2016 Operating and Financial Results 80

9.2.28 Aug 09, 2016: Zogenix Provides Corporate Update and Reports Second Quarter 2016 Financial Results 81

9.2.29 Aug 08, 2016: ICU Medical Announces Second Quarter 2016 Results 82

9.2.30 Jul 28, 2016: Boston Scientific Announces Results For Second Quarter 2016 83

9.2.31 Jul 26, 2016: Baxter Reports Second Quarter 2016 Results and Raises Financial Outlook for Full-Year 2016 84

9.3 Government and Public Interest 85

9.3.1 Mar 31, 2017: City Of Austin Announces Merck Economic Development Proposal 85

9.3.2 Sep 27, 2016: Orange County Business Council Study Showcases Economic Impact of Allergan on California Economy 86

9.4 Legal And Regulatory 86

9.4.1 Dec 22, 2016: Teva Pharmaceutical Paying $519 Million to Settle FCPA Charges 86

9.4.2 Nov 17, 2016: New Data from Global aHUS Registry Presented at ASN 2016 Show a Three-Fold Reduction in Post-Transplant Dialysis in Patients Initiating Soliris (eculizumab) Treatment Prior to Transplant Compared to Initiating Treatment Post-Transplant 87

9.5 Other Significant Developments 88

9.5.1 Jun 27, 2017: Boston Scientific Outlines Strategy for Sustained Growth at 2017 Investor Day 88

9.5.2 Jan 25, 2017: Daktari Achieves Milestone in Its Merck HCV Collaboration 90

10 Appendix 91

10.1 Research Methodology 92

10.1.1 Coverage 92

10.1.2 Secondary Research 92

10.1.3 Primary Research 93

10.1.4 Company Share Analysis 93

10.1.5 Distribution Share Analysis 93

10.1.6 Benchmarking 94

10.2 GlobalData Consulting 94

10.3 Contact Us 95

10.4 Disclaimer 95

1.2 List of Figures

Figure 1: Needle Free Injections Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2009-2023 8

Figure 2: Needle Free Injections Market, North America, Revenue ($m), Historic, USD Constant, 2009-2016 10

Figure 3: Needle Free Injections Market, North America, Revenue ($m), Forecast, USD Constant, 2016-2023 11

Figure 4: Needle Free Injections Market, North America, Volume (Units), 2009-2023 12

Figure 5: Needle Free Injections Market, North America, Volume (Units), Historic, 2009-2016 13

Figure 6: Needle Free Injections Market, North America, Volume (Units), Forecast, 2016-2023 14

Figure 7: Needle Free Injections Market, North America, Company Share (%) 2016 15

Figure 8: Needle Free Injections Market, Canada, Revenue ($m), USD Constant, Historic, 2009-2016 17

Figure 9: Needle Free Injections Market, Canada, Revenue ($m), USD Constant, Forecast, 2016-2023 18

Figure 10: Needle Free Injections Market, Canada, Volume (Units), Historic, 2009-2016 19

Figure 11: Needle Free Injections Market, Canada, Volume (Units), Forecast, 2016-2023 20

Figure 12: Needle Free Injections Market, Canada, Company Share (%) 2016 23

Figure 13: Needle Free Injections Market, Mexico, Revenue ($m), USD Constant, Historic, 2009-2016 25

Figure 14: Needle Free Injections Market, Mexico, Revenue ($m), USD Constant, Forecast, 2016-2023 26

Figure 15: Needle Free Injections Market, Mexico, Volume (Units), Historic, 2009-2016 27

Figure 16: Needle Free Injections Market, Mexico, Volume (Units), Forecast, 2016-2023 28

Figure 17: Needle Free Injections Market, Mexico, Company Share (%) 2016 31

Figure 18: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 33

Figure 19: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 34

Figure 20: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 35

Figure 21: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 36

Figure 22: Needle Free Injections Market, United States, Company Share (%) 2016 39

1.1 List of Tables

Table 1: Needle Free Injections Market, Cross Country Comparison, North America, Revenue ($m), USD Constant, 2009-2023 9

Table 2: Needle Free Injections Market, North America, Revenue ($m), Historic, USD Constant, 2009-2016 10

Table 3: Needle Free Injections Market, North America, Revenue ($m), Forecast, USD Constant, 2016-2023 11

Table 4: Needle Free Injections Market, North America, Volume (Units), 2009-2023 12

Table 5: Needle Free Injections Market, North America, Volume (Units), Historic, 2009-2016 13

Table 6: Needle Free Injections Market, North America, Volume (Units), Forecast, 2016-2023 14

Table 7: Needle Free Injections Market, North America, Company Share by Revenue ($m), USD Constant, 2016 16

Table 8: Needle Free Injections Market, Canada, Revenue ($m), USD Constant, Historic, 2009-2016 17

Table 9: Needle Free Injections Market, Canada, Revenue ($m), USD Constant, Forecast, 2016-2023 18

Table 10: Needle Free Injections Market, Canada, Volume (Units), Historic, 2009-2016 19

Table 11: Needle Free Injections Market, Canada, Volume (Units), Forecast, 2016-2023 20

Table 12: Needle Free Injections Market, Canada, Average Price ($), Historic, 2009-2016 21

Table 13: Needle Free Injections Market, Canada, Average Price ($), Forecast, 2016-2023 21

Table 14: Needle Free Injections Market, Canada, Distribution Share by Revenue ($m), USD Constant, 2015-2016 22

Table 15: Needle Free Injections Market, Canada, Company Share by Revenue ($m), USD Constant, 2016 24

Table 16: Needle Free Injections Market, Mexico, Revenue ($m), USD Constant, Historic, 2009-2016 25

Table 17: Needle Free Injections Market, Mexico, Revenue ($m), USD Constant, Forecast, 2016-2023 26

Table 18: Needle Free Injections Market, Mexico, Volume (Units), Historic, 2009-2016 27

Table 19: Needle Free Injections Market, Mexico, Volume (Units), Forecast, 2016-2023 28

Table 20: Needle Free Injections Market, Mexico, Average Price ($), Historic, 2009-2016 29

Table 21: Needle Free Injections Market, Mexico, Average Price ($), Forecast, 2016-2023 29

Table 22: Needle Free Injections Market, Mexico, Distribution Share by Revenue ($m), USD Constant, 2015-2016 30

Table 23: Needle Free Injections Market, Mexico, Company Share by Revenue ($m), USD Constant, 2016 32

Table 24: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Historic, 2009-2016 33

Table 25: Needle Free Injections Market, United States, Revenue ($m), USD Constant, Forecast, 2016-2023 34

Table 26: Needle Free Injections Market, United States, Volume (Units), Historic, 2009-2016 35

Table 27: Needle Free Injections Market, United States, Volume (Units), Forecast, 2016-2023 36

Table 28: Needle Free Injections Market, United States, Average Price ($), Historic, 2009-2016 37

Table 29: Needle Free Injections Market, United States, Average Price ($), Forecast, 2016-2023 37

Table 30: Needle Free Injections Market, United States, Distribution Share by Revenue ($m), USD Constant, 2015-2016 38

Table 31: Needle Free Injections Market, United States, Company Share by Revenue ($m), USD Constant, 2016 40

Table 32: Needle Free Injections Market Pipeline Products 43

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

INJEX-Equidyne Systems

Bioject Medical Technologies Inc

Antares Pharma Inc

PharmaJet Inc

MK Global Co.

Drug Delivery Devices, Central Venous Catheters, Needle Free Injections, Infusion Systems, Metered Dose Inhaler Devices, Value (USD), Volume (units), Revenues, Historic Revenues, Forecast Revenues, Average Price, Company Share, Distribution Share by Revenue, Company Share by Revenue, Pipeline Products, News, Deals, Key Companies, GlaxoSmithKline Plc, AstraZeneca Plc, Boehringer Ingelheim GmbH, Pfizer Inc, Merck & Co Inc, Sunovion Pharmaceuticals Inc, Teva Pharmaceutical Industries Ltd, INJEX-Equidyne Systems, Bioject Medical Technologies Inc , Antares Pharma Inc, PharmaJet Inc, MK Global Co., The European Pharma Group, Hospira Inc, Becton Dickinson and Co, Baxter International Inc, Fresenius Kabi AG, Medtronic plc, B. Braun Melsungen AG, Terumo Corp, Smiths Medical, Nipro Corp, JMS Co Ltd

select a license

Single User License
USD 5995 INR 404363
Site License
USD 11990 INR 808726
Corporate User License
USD 17985 INR 1213088

NEWSLETTER BY CATEGORY




Testimonials

An excellent provider. Thorough, precise and outstanding insight. They drill down to what we need and their reports are effective at integrating text with supporting graphics and charts. Their reports are a great resource to go back too. ...

Coherent, high-quality, thoroughly-researched reports. We received a very quick response to all our queries which eventually expedited the entire process....

Well structured, the insights they shared with us were very helpful and reliable. Their timely assistance make their services invaluable to us. I would highly recommend them and would definitely use them again in the future if needed...

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...



Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com